COVID-19 in Children with West Syndrome: An Ambispective Study

Priyanka Madaan1 · Lokesh Saini1 · Pooja Dhir1 · Sahil Vikas2 · Chandana Bhagwat1 · Mallika Goel2 · Akshita Soni2 · Jitendra Kumar Sahu1

Received: 12 November 2021 / Accepted: 6 February 2022 / Published online: 16 June 2022
© The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation 2022

Abstract
Objectives To study the course of West syndrome (WS) and coronavirus disease-19 (COVID-19) in children with WS who contracted SARS-CoV-2 infection.
Methods This ambispective study was conducted at a tertiary-care center in North India between December 2020 and August 2021 after approval from the Institute Ethics Committee. Five children with WS, positive for COVID-19 based on RT-PCR, fulfilled the inclusion criteria.
Results One child with COVID-19 during the first wave was retrospectively included while four children (of the 70 children screened) were prospectively enrolled. The median age at onset of epileptic spasms was 7 mo (2 boys), and that at presentation with COVID-19 was 18.5 mo. Three had underlying acquired structural etiology. Three were in remission following standard therapy, while two had ongoing spasms at the time of COVID-19 illness. During the illness, two of those in remission continued to be in remission while one child had a relapse. The children with ongoing epileptic spasms had variable course [one had persistent spasms and other had transient cessation lasting 3 wk from day 2 of COVID-19 illness, but electroencephalography (on day 8 of COVID-19 illness) continued to show hypsarrhythmia]. Fever was the most typical symptom (and sometimes the only symptom) of COVID-19, with a duration ranging from 1–8 d. Two children had moderate COVID-19 illness requiring hospitalization, while the rest had a mild illness. All the affected children had complete recovery from COVID-19.
Conclusion The severity of COVID-19 illness in children with WS is often mild, while the subsequent course of WS is variable.

Keywords Infantile spasms syndrome · Infantile spasms · Epileptic spasms · Children with epilepsy · Coronavirus disease 2019

Introduction
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an inevitable part of our lives. With over 240 million cases and 4.9 million deaths reported across more than 200 countries, the rate of infection and disease severity in children increased during the ongoing second wave of the pandemic in many countries [1]. Although the occurrence of de novo seizures in patients with COVID-19 is well-described, seizure is rarely a presenting feature of COVID-19 [2, 3]. Comorbid COVID-19 in persons with epilepsy (PWE) has been less frequently reported. A recent study revealed that COVID-19 in PWE was not associated with more severe illness. However, seizures as presenting manifestation of COVID-19 were more frequent in PWE (median age 41 y) than in people without epilepsy [4]. While acute symptomatic seizures or worsening epilepsy control in children with epilepsy (CWE) have been less commonly reported with COVID-19, the pandemic has gravely impacted the care of CWE [5, 6]. The occurrence of COVID-19 in a child with pre-existing epilepsy may have varied implications depending on the type of epilepsy or epilepsy syndrome, and ongoing medications.

In this regard, West syndrome (WS) constitutes a distinctive condition considering the peculiar management options (hormonal therapy), need for frequent follow-up, and higher
risk of severe COVID-19 in infants [7–9]. Unlike other epilepsies, acute febrile illnesses and pyretotherapy (artificial fever therapy) have been associated with spontaneous remission of epileptic spasms and resolution of hypsarrhythmia in children with WS [10]. However, the role of ongoing hormonal therapy in children with WS in modulating COVID-19 severity is debatable [8, 9]. Besides, COVID-19 has been associated with varied new neurological manifestations in children and there are specific concerns for children with neurological disorders [11, 12]. Hence, it is important to understand the implications of COVID-19 in children with WS. The current study provides a glimpse of COVID-19 and WS severity in children with WS who contracted SARS-CoV-2 infection.

**Material and Methods**

This ambispective study was conducted at a tertiary-care center in North India after approval from the Institute Ethics Committee (vide IEC-10/2020-1798). The study was carried out between December 2020 and August 2021. The primary objective of the study was to collate cases and collect data regarding clinical and laboratory features, treatments, and outcomes in children with WS who develop COVID-19. The secondary objectives included the determination of the disease course of WS and COVID-19.

Children (aged < 24 mo) diagnosed with WS [epileptic spasms with suggestive electroencephalography (EEG), fulfilling the West Delphi consensus criteria], who contracted COVID-19 were enrolled [13]. For the enrolled children, demographic details, age at onset of epileptic spasms, age at initiation of first-line therapy, lead time to treatment (LTTT), etiology, treatment received, response to treatment, number of relapses, etc., were ascertained by retrospective review and history from parents. Clinical details of COVID-19 [symptoms, results of investigations including COVID-19 RT-PCR, and clinical severity requiring transfer to intensive care unit, mechanical ventilation, progression to septic shock, and COVID-19-related death] were also noted. Comorbidities, comedications, and treatments administered explicitly for COVID-19 were also recorded.

Data were recorded in a Microsoft Excel spreadsheet (Microsoft Office, Microsoft Corp., Seattle, WA, USA). Variables were presented with continuous data as median (interquartile range; IQR) and categorical data as the frequency with percentage. The statistical analysis was done using SPSS 22.0.

**Results**

Of the seventy children with WS screened for febrile or respiratory illnesses or family history of COVID-19 during the study period, 10 had a febrile illness. Eight of these 10 children underwent COVID-19 RT-PCR and 4 children were positive for COVID-19. One child with COVID-19 during the first wave was retrospectively included while 4 children (of the 70 children screened) were prospectively enrolled after informed consent. Hence, 5 children fulfilled the inclusion criteria and participated in the study.

The median age at onset of epileptic spasms was 7 mo (2 boys) with a median LTTT of 9 wk (Table 1). Three of the 5 children have underlying acquired structural etiology [1 with presumed genetic developmental and epileptic encephalopathy (DEE) and 1 with tuberous sclerosis (TSC)], while all had hypsarrhythmia in pretreatment EEG (Fig. 1). Despite receiving multiple therapies before SARS-CoV-2 infection, 2 had ongoing spasms (1 was gaining developmental milestones while the other had developmental stagnation). During the COVID-19 illness, one of them had no significant change in spasm frequency, while the other had transient cessation of clinical spasms since day 2 of illness lasting for 3 wk (although the EEG continued to show hypsarrhythmia on day 8 of illness). After the transient cessation, there was a recurrence of epileptic spasms with clustering and progressive worsening with developmental stagnation followed by regression.

The other 3 children were spasm-free for a median period of 10 wk before the onset of COVID-19 illness. One of them (the child with TSC) had a relapse with recurrence of spasms during the COVID-19 illness, while the other 2 (underlying etiology: DEE and hypoxic brain injury) continued to be spasm-free till the last follow-up (Fig. 1). The child with relapse responded to a hike in the dose of vigabatrin and has been spasm-free. The child with presumed DEE had transient worsening of movement disorder during the COVID-19 illness, which settled spontaneously by day 5 of illness.

The median age at presentation with COVID-19 was 18.5 mo (range: 13–23 mo; Table 2). Fever was the most typical symptom seen in all children, with a duration ranging from 1–8 d. Two children had moderate disease (possibly with comorbid aspiration pneumonitis) requiring hospitalization. All the affected children had a complete recovery from COVID-19.

**Discussion**

The present study illustrates the disease course of WS and comorbid COVID-19 in 5 Indian children. With WS comprising nearly 2% of childhood epilepsies and children constituting less than 10% of the COVID-19 cohorts, comorbid WS and COVID-19 are probably rare [14, 15]. Since many children and infants are asymptomatic or mildly symptomatic with upper respiratory symptoms (which are otherwise seen with any viral infection and often settle), the infrequent COVID-19 testing in this age group might be contributory to
Table 1  Baseline characteristics of West syndrome and the impact of COVID-19

| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|---------------|-----------|-----------|-----------|-----------|-----------|
| Age at onset of spasms | 4 mo | 17 mo | 6 mo | 13 mo | 7 mo |
| Gender | Female | Male | Male | Female | Female |
| Lead time to first-line therapy | 20 wk | 8 wk | 12 wk | 8 wk | 9 wk |
| Neurological comorbidities | Developmental delay | Developmental delay, evolving cerebral palsy | Developmental delay, movement disorder | Mild autistic symptoms | Developmental delay, evolving cerebral palsy |
| Etiology | Structural; hypoglycemic brain injury | Structural; hypoxic brain injury | Presumed genetic developmental and epileptic encephalopathy | Tuberosclerosis | Structural; hypoxic brain injury |
| Brain MRI findings | Bilateral parieto-occipital gliosis | Bilateral periventricular signal changes, diffuse atrophy | Mild diffuse atrophy | Multiple cortical tubers | Bilateral periventricular signal changes and volume loss |
| Pretreatment EEG findings | Modified hypsarrhythmia | Hypsarrhythmia | Hypsarrhythmia | Hypsarrhythmia | Modified hypsarrhythmia |
| First-line and second-line therapies received | ACTH, VGB, prednisolone, VPA, ZNS, TPM, NTZ | Prednisolone, ACTH, VPA, CLN | VGB, ACTH, VPA | VGB (75 mg/kg/d) | ACTH, VPA, LEV, CLN |
| First-line therapy to which the child responded | Partly responded to ACTH and VGB combination | ACTH | ACTH | VGB | Initially, responded to ACTH. Subsequently, had relapse which did not respond to prednisolone |
| Ongoing spasms before COVID-19 | Yes; isolated spasms | No; spasm-free for last 10 wk | No; spasm-free for last 4 wk | No; spasm-free for last 12 wk | Yes; clustered spasms |
| Effect of COVID-19 on spasm frequency | Transient cessation for 3 wk (EEG after 8 d of cessation showed hypsarrhythmia) | No change; had persistent cessation during the COVID-19 illness | No change; had persistent cessation during the COVID-19 illness; no relapse | Relapse with recurrence of clustered spasms after 1 wk of fever | No change; had ongoing spasms as before |
| Effect of COVID-19 on other neurological symptoms | - | - | Transient worsening of movement disorder (tremulousness, dystonia) lasting 5d | - | |
| Final outcome | Persisting clustered epileptic spasms, with developmental regression | Resolution with persistent cessation + no relapse | Resolution with persistent cessation + no relapse | Spasms responded to increased dose of VGB (100 mg/kg/d) within 3 d | Persisting clustered epileptic spasms, more than >50% reduction in spasms with VGB (started at discharge) |
| Last follow-up after COVID-19 | 12 mo | 3 mo | 3 mo | 3 mo | 2 mo 3 wk |

ACTH Adrenocorticotropic hormone, CLN Clonazepam, COVID-19 Coronavirus disease 2019, EEG Electroencephalography, MRI Magnetic resonance imaging, NTZ Nitrazepam, TPM Topiramate, VGB Vigabatrin, VPA Sodium valproate, ZNS Zonisamide
the lower rate of detection of cases. Under-testing in infants and young children is not just limited to developing countries. As seen in a Spanish study, among 15 children with DEE with typical COVID-19 symptoms, only 7 were tested with RT-PCR [5].

Since the children with WS were being followed-up with teleconsultations during the first COVID-19 wave at the study site (due to several research studies going on in the department), a higher number of children with WS were observed to be infected during the second wave as compared with the first wave (although denominator for the first wave is not available). This goes in hand with the higher number of children infected during the second wave (probably due to vaccination in adults and easing of lockdown restrictions) [16, 17]. Also, for the subsequent surges of COVID-19, it has been contemplated that the children might bear the brunt of the COVID-19 vaccine rollout strategy (older adults followed by young adults and children) due to the unvaccinated status.

Unlike all the previously reported children with DEE or infantile spasms (with genetic or presumed genetic etiology) with COVID-19, 3 of 5 children in the current study had underlying acquired structural etiology [5, 18]. This concurs with a predominance of structural etiology in developing countries [19–21]. Also, the treatment lag (like previous studies) was huge in all 5 children, despite which, 3 had responded and were in remission [19, 22].

Similar to previous reports of SARS-CoV-2 infection in 3 children with DEE and 1 child with cryptogenic WS (in remission), the COVID-19 illness was mild to moderate in the present case series [5, 18]. Although none of the previously reported children with DEE had either seizure or behavioral worsening during the COVID-19 illness, the previously reported child with cryptogenic WS had a relapse after 14 mo of cessation of spasms and was incidentally detected to be COVID positive on screening (asymptomatic for COVID-19) [5, 18]. The disease course in the present study was different, with 1 child having persistent worsening after a transient cessation, 1 child having a relapse (which responded to hike in vigabatrin), while the other 3 had unchanged spasm frequency (2 in remission and 1 with ongoing spasms).

Body temperature plays a critical role in determining seizure threshold and seizure-related brain damage [23]. High-grade fever and febrile illnesses are often known to worsen seizure control (for most convulsive seizure types) by lowering the seizure threshold [23]. In this context, epileptic spasm is a unique seizure semiology where spontaneous resolution has been reported after fever (pyretotherapy) [10, 24]. The possible reasons for this phenomenon include increased plasma concentrations of endogenously secreted adrenocorticotropic hormone (ACTH) and steroidal hormones in response to stressors, including infections and fever [10].
Table 2  Characteristics of COVID-19 illness in children with West syndrome

| Characteristic                        | Patient 1                          | Patient 2                          | Patient 3                          | Patient 4                          | Patient 5                          |
|---------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Age at presentation with COVID-19     | 18.5 mo                             | 23 mo                               | 13 mo                               | 19 mo                               | 18 mo                               |
| Contracted COVID-19 during            | 1st wave                           | 2nd wave                            | 2nd wave                            | 2nd wave                            | 2nd wave                            |
| Ongoing drugs for West syndrome       | VPA, ZNS, and NTZ (Off ACTH for last 6 mo) | VPA and CLN (Off ACTH for last 4 wk) | VPA (Off ACTH for last 2 wk)         | VGB                                 | VPA, LEV, CLN, and prednisolone     |
| COVID-19 symptom profile              |                                    |                                     |                                     |                                     |                                     |
| Fever                                 | Yes; moderate to high grade, lasted 6 d | Yes; moderate to high grade, lasted 2 d | Yes; moderate to high grade, lasted 5 d | Yes; moderate grade fever for 1 d | Yes; high grade for 8 d               |
| Cough                                 | Yes                                 | No                                  | No                                  | No                                  | Yes                                 |
| Respiratory distress                  | Tachypnea and noisy breathing, lasted 7 d | No                                  | No                                  | No                                  | Tachypnea and noisy breathing, lasted 10 d |
| Caregivers affected                   | No; COVID negative                  | Fever in mother and sister but both COVID negative | Yes; both parents COVID positive | Yes; both parents COVID positive | No; COVID negative                   |
| Need for respiratory support          | Yes; low-flow oxygen by nasal prongs; required for 5 d | -                                   | -                                   | -                                   | Yes; nasal CPAP followed by oxygen by nasal prongs; required for 10 d |
| Other concerns (vasopressor support, renal dysfunction, liver dysfunction) | -                                   | -                                   | -                                   | -                                   | Had compensated shock requiring 1 bolus at admission |
| COVID-19 severity                     | Moderate disease (respiratory distress, radiographic evidence of pneumonia) | Mild (not requiring hospitalization) | Mild (not requiring hospitalization) | Mild (not requiring hospitalization) | Moderate disease (respiratory distress, radiographic evidence of pneumonia, compensated shock) |
| Drugs used for respiratory illness    | Amoxicillin+clavulanic acid, oseltamivir | -                                   | -                                   | -                                   | Amoxicillin+clavulanic acid, ceftriaxone |
| Final outcome of respiratory illness  | Complete recovery                   | Complete recovery                    | Complete recovery                    | Complete recovery                    | Complete recovery                    |

ACTH Adrenocorticotrophic hormone, CLN Clonazepam, COVID-19 Coronavirus disease 2019, CPAP Continuous positive airway pressure, NTZ Nitrazepam, VPA Sodium valproate, ZNS Zonisamide
The clinical course and EEG changes following pyretotherapy resemble that following hormonal therapy with clinical cessation reported in most patients by day 4 of fever while hypsarrhythmia resolution occurs by day 6–8 [10]. In the present study, the child with transient cessation of epileptic spasms did not have hypsarrhythmia resolution. EEG could be done only once during illness due to COVID-19–related constraints and resource-limited setting. Following the ACTH therapy initially, she had exhibited > 50% reduction in spasm frequency. The authors believe that the response to pyretotherapy in WS might also depend on the tendency to respond to hormonal therapy in general, LTITT, age at onset, etc. However, the progressive developmental deterioration in this child might be due to subsequent worsening of epileptic encephalopathy. Also, the child with TSC had a brief febrile phase lasting 24 h, and she developed transient relapse after 1 wk of subsidence of fever (due to COVID-19). Duration of fever due to COVID-19 might affect the course of WS in some patients during and after COVID-19 illness.

The current study attempted to describe the implications of SARS-CoV-2 infection in children with WS. With only one previous report of COVID-19 in a child with WS, this case series is a significant addition to the literature. However, due to the few children in the study, it is not easy to draw robust conclusions. Furthermore, due to the pandemic restrictions, EEG changes during the COVID-19 illness could not be studied for children who did not require hospitalization.

Conclusion

Comorbid COVID-19 in children with WS may be underdiagnosed. The severity of COVID-19 illness in children with WS is often mild, while the subsequent course of WS is variable. Proactive COVID-19 testing is desirable in children with WS presenting with fever with or without respiratory symptoms, depending on the regional COVID-19 transmission. Multicenter data would be helpful for further understanding of the repercussions of COVID-19 in children with WS.

Authors’ Contributions PM contributed by planning of the study, literature search, patient management, data collection, data analysis, and writing of the manuscript; PD contributed by data collection, data analysis, and critical review of the manuscript for intellectual content; LS, SV, CB, MG, and AS contributed by patient management and critical review of the manuscript for intellectual content; JKS contributed by conception and planning of the study, patient management, data analysis, data interpretation, and writing of the manuscript. All authors approved the final version of manuscript to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. JKS will act as the guarantor for this paper.

Funding  None.

Declarations

Ethical Publication Statement  The authors confirm that they have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Conflict of Interest  None.

References

1. World Health Organization. Coronavirus. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed on 30 Dec 2021.
2. Asadi-Pooya AA, Simani L, Shahisavandi M, Barzegar Z. COVID-19, de novo seizures, and epilepsy: a systematic review. Neuror Sci. 2021;42:415–31.
3. Keshavarzi A, Janbabaei G, Kheyrrati L, Ghavamabad LH, Asadi-Pooya AA. Seizure is a rare presenting manifestation of COVID-19. Seizure. 2021;86:16–8.
4. Asadi-Pooya AA, Emarni A, Akbari A, Javanmardi F. COVID-19 presentations and outcomes in patients with epilepsy. Acta Neurol Scand. 2021;143:624–8.
5. Aledo-Serrano Á, Mingorance A, Jiménez-Huete A, et al. Genetic epilepsies and COVID-19 pandemic: Lessons from the caregiver perspective. Epilepsia. 2020;61:1312–4.
6. Wirrell EC, Grinspan ZM, Knupp KG, et al. Care delivery for children with epilepsy during the COVID-19 pandemic: an international survey of clinicians. J Child Neurol. 2020;35:924–33.
7. Grinspan ZM, Mytinger JR, Baumer FM, et al. Management of infantile spasms during the covid-19 pandemic. J Child Neurol. 2020;35:828–34.
8. Sahu JK, Madaan P, Chand P, et al. Management of west syndrome during covid-19 pandemic: a viewpoint from South Asian west syndrome research group. Epilepsy Res. 2020;167:106453.
9. Madaan P, Sahu JK, Waniqasinghe J, et al. Teleneurology based management of infantile spasms during COVID-19 pandemic: A consensus report by the South Asia Allied West syndrome research group. Epilepsy Behav Rep. 2021;15:100423.
10. Sugiura C, Maegaki Y, Kure H, Inoue T, Ohno K. Spontaneous remission of infantile spasms and hypsarrhythmia following acute infection with high-grade fever. Epilepsy Res. 2007;77:102–7.
11. Madaan P, Singamamulla B, Saini L. Neurological manifestations of covid-19 in children: time to be more vigilant. Pediatr Neurol. 2021;115:28.
12. Gupta J, Madaan P, Gulati S. COVID-19: Implications for children with special needs. Journal for ReAttach therapy and developmentals diversities. 2020;3:1–3.
13. Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and west syndrome: consensus statement of the West Delphi group. Epilepsia. 2004;45:1416–28.
14. Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia. 2015;56:1185–97.
15. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088–95.
16. Ghosh A. More 0–19 yr olds falling sick in India’s second Covid wave than last time, says ICMR. The Print. Available at: https://theprint.in/health/more-0-19-yr-olds-falling-sick-in-indias-second-covid-wave-than-last-time-says.icmr/640608/. Accessed on 26 Dec 2021.

17. COVID-19 and children. UNICEF. Available at: https://www.unicef.org/india/coronavirus/covid-19/covid-19-and-children. Accessed on 26 Dec 2021.

18. Dygert L, Eichelberger H, Nelson A. Recurrence of Infantile spasms in the setting of COVID-19 infection. Neurology. 2021;96:1823.

19. Madaan P, Chand P, Linn K, et al. Management practices for West syndrome in South Asia: a survey study and meta-analysis. Epilepsia Open. 2020;5:461–74.

20. Bhanudeep S, Madaan P, Sankhyan N, et al. Long-term epilepsy control, motor function, cognition, sleep and quality of life in children with West syndrome. Epilepsy Res. 2021;173:106629.

21. Wanigasinghe J, Sahu JK, Madaan P, et al. Classifying etiology of infantile spasms syndrome in resource-limited settings: A study from the South Asian region. Epilepsia Open. 2021;6:736–47.

22. Aramanadka R, Sahu JK, Madaan P, Sankhyan N, Malhi P, Singhi P. Epilepsy and neurodevelopmental outcomes in a cohort of West syndrome beyond two years of age. Indian J Pediatr. 2021. https://doi.org/10.1007/s12098-021-03918-y.

23. Gulcibi MI, Bartolini E, Lee O, et al. Climate change and epilepsy: insights from clinical and basic science studies. Epilepsy Behav. 2021;116:107791.

24. Garcia de Alba GO, García AR, Crespo FV. Pyretherapy as treatment in West’s syndrome. Clin Electroencephalogr. 1984;15:140–4.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.